In case series or subset of cases in which advanced, high stage, clinically aggressive thyroid cancers are overrepresented either as pTs or as DMs [9], the prevalence of TERT amplification results much higher (29.4%) than in series in which the commonest histotype, as occurs in the TCGA thyroid research project [5], is a conventional, low/intermediate risk PTC (4.4–5%). The gene discussed is TERT; the disease is thyroid gland disorder.